选择性环氧化酶-2抑制剂对心血管影响的研究进展  

Research progress on the effect of selective COX-2 inhibitors on cardiovascular diseases

作　　者：杨鹰[1] 孙茹[2] 曹艳花[2] 

机构地区：[1]中国人民解放军第四○一医院高压氧科,山东青岛266071 [2]山东大学附属省立医院药剂科,山东济南250021

出　　处：《药学研究》2016年第1期41-45,共5页Journal of Pharmaceutical Research

基　　金：北京市科委首都市民健康项目培育科研基金资助项目(No.Z12110200750000)

摘　　要：目的综述选择性环氧化酶-2抑制剂在心血管方面的安全性及其作用机制。方法通过查阅国内外相关文献,分别比较归纳了不同选择性环氧化酶-2抑制剂引发心血管事件的风险性,并总结了罗非昔布、塞来昔布等对心血管的作用机制。结果对选择性环氧化酶-2抑制剂引发心血管不良反应的研究进展进行了比较全面的总结。结论不同选择性环氧化酶-2抑制剂在心血管安全性方面有明显差别,比较几种昔布类药物,塞来昔布相对安全,与小剂量阿司匹林联合服用可降低心血管风险性。Objective To review the effect of selective COX- 2 inhibitors on cardiovascular diseases and their mechanisms. Methods By consulting related references,the risk of cardiovascular events caused by different selective COX- 2inhibitors was compared,and the effect mechanisms of rofecoxib and celecoxib on cardiovascular system were summarized. Results The research progress of selective COX- 2 inhibitors and adverse cardiovascular events were comprehensively summarized. Conclusion A different risk profile for COX- 2 inhibitors had emerged. Compared to rofecoxib and other coxibs,celecoxib was relatively safe. Receiving celecoxib with low- dose aspirin was recommended to exhibit lower cardiovascular risk.

关 键 词：环氧化酶-2 心血管 塞来昔布 罗非昔布 

分 类 号：R541.4[医药卫生—心血管疾病]